China’s NMPA accepts a marketing authorization application for foritinib following interim results from the phase III REMARK trial. Read more
Anti-obesity medications could theoretically reduce the absorption of oral TKIs, particularly in cases of lipophilicity, where therapeutic agents have a strong dependence on dietary fat for adequate dissolution. Read more
During a TTLC debate, Drs. Helena Yu and Shirish Gadgeel weighed the pros and limitations of osimertinib monotherapy and combination therapies. Read more
Lacking evidence to argue against combinations in this patient population, Dr. Penelope Bradbury, turned to humor to make her case. Read more
Dr. Karen Reckamp discusses the challenges that both patients and oncologists in the Los Angeles area experienced during the devastating fires. Read more
Though the study is small, the sponsor says results are promising for the first-in-class telomere-targeting agent. Read more
Data from the Beamion LUNG-1 trial show a 71% objective response rate in previously treated patients. Read more
Dr. Leticia Nogueira says the time has come for the lung cancer community to champion environmentally responsible practices that help mitigate cancer risks and outcomes. Read more
Patient Advocates Angus Pratt and Terri Ann DiJulio explore the key role that the medical community plays in helping patients and families understand the importance of palliative care. Read more
Durvalumab is recommended for approval in the EU, Health Canada approves pembrolizumab, and the US FDA grants priority review to datopotamab deruxtecan. Read more